Hispanic Patients Hospitalized with COVID-19 Disease-Characteristics and Clinical Outcomes at a Tertiary Care Center in New York City
Journal of Advances in Medicine and Medical Research,
Background: COVID-19 disease has disproportionately affected ethnic minorities in the US.
Objective: To describe the characteristics and predictors of mortality and length of hospital stay (LOS) in patients of Hispanic ethnicity hospitalized for COVID-19 disease.
Design: Retrospective cohort study of 162 patients.
Setting: Tertiary care teaching hospital in Brooklyn, NY.
Patients: Hispanic patients hospitalized with principal diagnosis of COVID-19 disease between March 8, and April 25, 2020.
Methods: Patients were classified into mild/moderate, severe/very severe, and critical disease (intubated) based on oxygen requirements. The primary endpoint was overall mortality rate and the secondary endpoint was LOS.
Results: Mean age was 55.6 years and 40.1% had critical disease. The overall mortality was 35.8%. Increasing age (OR:1.09, 95% CI:1.04, 1.13, p<0.001) and vasopressor use (OR:198.55, 95% CI:15.89, 2480.66, p<0.001) were each independently associated with increased odds for mortality. Steroid use was significantly associated with decreased odds for mortality (OR:0.05, 95% CI:0.004, 0.61, p<0.05). Mean LOS was 14 days. Severe/very severe disease was significantly associated with increased LOS while critical disease was significantly associated with decreased LOS. The use of hydroxychloroquine, steroids, antibiotics, vasopressor, blood transfusion, and diagnosis of bacteremia/fungemia were each significantly associated with increased LOS. Spanish-speaking patients were older than English-speaking ones, however, there was no difference in mortality or LOS between the groups.
Conclusion: Age and vasopressor use was associated with increased mortality in Hispanics. Steroid use was associated with decreased mortality but increased LOS. No difference in outcomes was observed between English- and Spanish-speaking Hispanics.
- Covid-19 disease
- public health
How to Cite
Golestaneh L, Neugarten J, Fisher M, et al. The association of race and COVID-19 mortality. EClinicalMedicine. 2020. 1;25:100455.
CDC COVID Data Tracker.
Available:https://covid.cdc.gov/covid-data-tracker/#datatracker-home. January 2021.
Salud America. Update: Coronavirus Case Rates and Death Rates for Latinos in the United States.
Available:https://salud-america.org/coronavirus-case-rates-and-death-rates-for-latinos-in-the-united-states/ Cliff Despres. Accessed February 26, 2021.
Cheng KJ, Sun Y, Monnat SM. COVID‐19 death rates are higher in rural counties with larger shares of Blacks and Hispanics. J Rural Health. 2020.
United States Census Bureau. American Community Survery (ACS). Available:https://www.census.gov/programs-surveys/acs
Accessed January 2021.
Centers for Disease Control and Prevention.
Available:https://www.cdc.gov/nchs/nvss/vsrr/covid19/health_disparities.htm. January 2021.
Kabarriti R, Brodin NP, Maron MI, et al. Association of race and ethnicity with comorbidities and survival among patients with COVID-19 at an urban medical center in New York. JAMA Network Open. 2020,1;3(9):e2019795.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. DOI: 10.1016/S0140-6736(20)30566-3.
Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020;382(21):2012-2022.
Raheja H, Chukwuka N, Agarwal C, et al. Should COVID-19 patients > 75 years be ventilated? An Outcome Study. QJM. 2021 DOI: 10.1093/qjmed/hcab029.
Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people?. Aging (Albany NY). 2020 31;12(10):9959.
Baqui P, Bica I, Marra V, et al. Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study. Lancet Global Health. 2020;8(8):e1018-26.
Rodriguez F, Solomon N, de Lemos JA, et al. Racial and ethnic differences in presentation and outcomes for patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry. Circulation. 2020.
Rojas-Marte G, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM. 2020;113(8):546-550.
Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-1770.
Ling L, So C, Shum HP, et al. Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study. Crit Care Resusc. 2020;22(2):119-125.
Michard F, Malbrain ML, Martin GS, et al. Haemodynamic monitoring and management in COVID-19 intensive care patients: an international survey. Anaesth Crit Care Pain Med. 2020;39(5):563- 9.
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020: NEJMoa2021436.
Tomazini BM, Maia IS, Cavalcanti AB, et al; COALITION COVID-19 Brazil III Investigators. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA. 2020;324(13):1–11.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1–13.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med 2020; 383:1813-1826.
Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12(7):6049-6057. DOI: 10.18632/aging.103000.
DuBard CA, Gizlice Z. Language spoken and differences in health status, access to care, and receipt of preventive services among US Hispanics. Am J Public Health. 2008;98(11):2021-8.
Cheng E.M., Chen A., Cunningham W. Primary language and receipt of recommended health care among Hispanics in the United States. J Gen Intern Med. 2007;22:283–238.
Johnstone M, Kanitsaki O. Cultural racism, language prejudice and discrimination in hospital contexts: an Australian study. Divers Health Soc Care. 2008;5:19–30.
John-Baptiste A, Naglie G, Tomlinson G, et al. The effect of English language proficiency on length of stay and in-hospital mortality. J Gen Intern Med. 2004;19:221–228.
Karliner LS, Kim SE, Meltzer DO, et al. Influence of language barriers on outcomes of hospital care for general medicine inpatients. J Hosp Med. 2010;5:278–282.
Abstract View: 273 times
PDF Download: 122 times